TraceLink Inc. said yesterday that it raised $51.5 million in a Series C financing round, bringing its total raised to $77 million. The round was led by Goldman Sachs Growth Equity, joining FirstMark Capital, Volition Capital and F-Prime Capital.
TraceLink developed a cloud-based global network of manufacturers, distributors, pharmacies and healthcare professionals. The firm’s system enables any company within the pharmaceutical supply chain to track and trace authentic prescription medicines, which it says will be required by law in 50 countries by 2020.
Get the full story at our sister site, Drug Delivery Business News.
The post Counterfeit prescription drug tracker raises $52m appeared first on MassDevice.